Jade Biosciences, Inc. (JBIO)
JBIONASDAQ-CMBiotechnology: Pharmaceutical Preparations
$16.14
+0.2700 (+1.70%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $1.03bn
- P/E
- –
- EPS, last 4 quarters
- $-1.92
- Dividend yield
- –
- Day range
- –
- 52-week range
- $9.51 to $28.00
- Average volume
- –
- Previous close
- $15.87
Analysts
10 coveringBuy10 buy, 0 hold, 0 sell
Targets a year out average $52.67, +226.3% from here
Earnings
next estimate $-0.7300Next report
Sep 2025
+15.8%
Dec 2025
+75.6%
Mar 2026
-9.6%
Jun 2026
-15.2%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$34.98m | -$43.45m | -$58.92m | -$39.64m |
| Net income | -$31.93m | -$40.37m | -$55.77m | -$35.05m |
News
8 latest- Jade Biosciences Advances JADE301 Toward Phase 1 Trial In Dermatomyositis RTTNews · Sep 30, 2026
- Jade Bioscience Reports Preclinical Data For JADE301 RTTNews · Sep 30, 2026
- Jade Reports Wider Loss In Q2, Expects Autoimmune Pipeline Interim Data In FY27 RTTNews · Aug 10, 2026
- Jade Biosciences Appoints Mark Eisner To The Board Of Directors RTTNews · Jun 26, 2026
- Top Biotech Gainers: BOLD Begins Anew, MNPR NDA Filing On Track, GALT Soars On FDA Alignment RTTNews · Jun 23, 2026
- Jade Biosciences Prices $150 Mln Offering Of Shares At $15.00/shr; Stock Down RTTNews · Jun 4, 2026
- Jade Biosciences’ JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney TrialsMarketBeat · Jun 1, 2026
- Jade Doses First Participant In JUNIPER Phase 2 Trial Of JADE 101 In IgA Nephropathy RTTNews · May 27, 2026
The company
Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade's lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated for the treatment of immunoglobulin A nephropathy. Jade's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE301, an anti-IFN- monoclonal antibody. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit JadeBiosciences.com and follow the Company on LinkedIn.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- jadebiosciences.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.